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Centers for Medicare and Medicaid Services
conducts a medical evidence development and
coverage advisory committee meeting on carotid
atherosclerosis
Richard P. Cambria, MD, Boston, Mass
Publication of the eagerly anticipated Carotid Revascularization Endarterectomy Versus Stenting Trial in May 2010 was
anticipated to engender much activity in the realm of interventions for carotid stenosis. Specifically, a variety of
professional societies, including the Society for Vascular Surgery (SVS), published updated practice guidelines in the
calendar year 2011, timed to include data from large-scale well-conducted clinical trials comparing carotid endarterec-
tomy with carotid artery stenting (CAS). In anticipation of a renewed application to the Centers for Medicare and
Medicaid Services (CMS) to reconsider the national coverage determination for CAS, the SVS Board of Directors voted
in June 2011 against any change in the national coverage determination for CAS. CMS convened a Medicare evidence
development and coverage advisory committee (MEDCAC) meeting to consider fundamental aspects of the treatment of
carotid atherosclerosis on January 25, 2012, to allow an unbiased and current deliberation of the state-of-the-art
technology and science referable to the management of carotid atherosclerosis. The MEDCAC differs substantially from
a reconsideration of coverage determination and, in this case, was built around seven research questions. The MEDCAC
consists of a panel of experts who, after reviewing the literature and submitted comments by interested stakeholders, and
after hearing testimony from invited speakers and at-large presentations, held a panel vote on the research questions.
Given that management of carotid atherosclerosis is a core element of vascular surgical practice, the SVS had a major
presence at the MEDCAC in the form of a comprehensive written document individually considering the research
questions and a variety of presentations addressing various aspects in carotid disease management. The purpose of this
report is to detail the SVS’s position on the MEDCAC research questions referable to the management of carotid
atherosclerosis and to otherwise detail the proceedings of the MEDCAC. (J Vasc Surg 2012;56:e1-16.)
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iAt the present time, there is a national coverage deter-
mination (NCD) restricting reimbursement for carotid an-
gioplasty and stenting (CAS) to specifically defined patient
subsets (full details at http://www.cms.gov/medicare-
coverage-database/details/medcac-meeting-details.aspx?
MEDCACId62&bcAAAIAAAAAAA.). These include
symptomatic patients with 70% carotid stenosis who are
considered at high risk for carotid endarterectomy and/or
symptomatic or asymptomatic patients enrolled in U.S.
Food and Drug Administration-approved clinical trials or
high-risk registries. On a number of different occasions
(September 2006-CAG-00853R, February 2007-CAG-
0085R3, and March 2008-CAG-00885R6), the Society
for Vascular Surgery (SVS) has offered position statements
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http://dx.doi.org/10.1016/j.jvs.2012.04.051elated to the NCD for CAS; typically this has occurred in
he context of a reconsideration of the NCD for CAS.
onsistent with the position statements related in these
ommunications, at its June 2011 meeting, the SVS Board
f Directors, by a vote of 21 to 22, voted against any change
n the SVS position referable to the NCD for CAS at this
oint in time. This was in anticipation of another applica-
ion for reconsideration of the NCD for CAS in light of the
ublication of the Carotid Revascularization Endarterec-
omy Versus Stenting Trial (CREST). In fact, the corporate
osponsor of the CREST trial did submit such application
ut was denied in this regard by the Centers for Medicare
nd Medicaid Services (CMS).
Instead, CMS decided to convene a medical evidence
evelopment and coverage advisory committee meeting
MEDCAC), which is designed (as defined in the CMS
eb site) to “review and evaluate the medical literature,
echnology assessment, and vet public testimony on the
vidence available to address the impact of medical items
nd services on health outcomes inMedicare beneficiaries.”
he MEDCAC mechanism, established in 1998, is used to
upplement CMS’s internal expertise and allow an unbiased
nd current deliberation of the state-of-the-art technology
nd science. The MEDCAC consists of a pool of 100
ppointed members who are recognized authorities in clin-
cal medicine or disciplines, or both, related to clinical trial
vidence, such as epidemiology and biostatistics, health
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July 2012e2 Cambriacare management or economics (or both), patient advo-
cacy, or other relevant disciplines.
Participating members in the carotid atherosclerosis
MEDCAC of January 25, 2012 are detailed on the CMS
Web site, as is the rationale and detail of the seven research
questions referable to carotid atherosclerosis constituting
the subject matter of this particular MEDCAC. Specific
disciplines represented by the 15 sitting or invited guest
panel members for the MEDCAC included neurologists
(three), general internal medicine (four), health care policy
(four), and other disciplines, including nursing (one). An
industry representative was also present. Invited guest
speakers were allotted 20 minutes to present to the MED-
CAC panel, with such speakers clearly intended to repre-
sent a spectrum of disciplines and positions and perhaps
based on their prior publications. The invited guest speak-
ers at the MEDCAC included (alphabetical order):
1. Anne L. Abbott, MD, PhD, a research neurologist from
Australia, whose publications advocate optimal best
medical therapy (BMT) alone as sufficient treatment for
asymptomatic carotid stenosis.
2. Thomas G. Brott, MD, Professor of Neurology at the
Mayo Clinic and National Coprincipal Investigator of the
CREST trial, whose presentation largely centered on
the rationale for and design of a potential CREST 2 trial
whose design would entail randomization of patients with
asymptomatic high-grade stenoses to intervention (both
CEA and CAS) vs BMT.
3. Mark D. Grant, MD, MPH, Director, Technology
Evaluation Center, Blue Cross Blue Shield Association.
4. William A. Gray, MD, Associate Professor of Clinical
Medicine, Columbia University College of Physicians
and Surgeons. Dr Gray is widely published in the realm
of CAS registries and as anticipated advocated extending
reimbursement for CAS, based largely or exclusively on
CREST data.
5. Wesley S. Moore, MD, Professor and Chief Emeritus,
Division of Vascular Surgery, David Geffen School of
Medicine at the University of California, Los Angeles.
Dr Moore is the surgeon coprincipal investigator of the
national CREST trial and a recognized authority in the
management of carotid atherosclerosis over a long pe-
riod of time. Dr Moore was also the 2011 Lifetime
Achievement Award winner of the SVS. Dr Moore’s
testimony, while representing his personal views, was
ultimately entirely consistent with that of SVS.
The seven research questions detailed below were pub-
lished in the Federal Register. The preamble to the seven
research questions states:
The primary focus of the Medicare evidence development
and coverage advisory Committee (MEDCAC) meeting
is whether or not CAS, CEA, and BMT improve out-
comes in symptomatic and asymptomatic persons with
carotid atherosclerosis. In discussing the management of
such individuals, CMS is most interested in stroke preven- etion, and the health outcomes of interest are stroke (all
stroke) and death (all-cause mortality).
After the presentations and questioning by the panel
embers (largely confined to the invited speakers), the
anel voted on the six voting questions (a question on
nmet research needs was not a voting question) along a
ierarchal scale (1, low confidence; 5, high confidence) on
he adequacy of the published evidence referable to the
esearch questions. Panel Chair Clifford Goodman, PhD,
epeatedly emphasized that the MEDCAC was interested
n the adequacy of evidence rather than in opinion or
ndividual experience.
“Interested stakeholders” were invited to submit writ-
en comments on the research questions or apply to speak
ublicly at the MEDCAC, or both. Written comments to
he MEDCAC were submitted by SVS, as detailed below,
he American Heart Association (AHA)/American Stroke
ssociation, the American Academy of Neurology, and the
ociety of Interventional Radiology. The specific list of
ublic comment speakers is available on the CMS Web site
nd included a spokesman for the American Academy of
eurology, the American Association of Neurological Sur-
eons/Congress of Neurological Surgeons, the Society of
eurointerventional Surgery, the American College of
ardiology (ACC), the Society for Cardiovascular Angiog-
aphy and Intervention, and the Society for Vascular Med-
cine. The Chief Medical Officer of Abbott Vascular also
resented.
All at-large speakers were limited to 4 minutes. SVS
peakers comprised six of 14 at-large speakers, all of whom
re required to register and submit presentations a month
n advance of the MEDCAC. SVS, to augment its extensive
ritten comments and reflect the importance of carotid
isease management to its members, offered six presenta-
ions, detailed below, delivered in large part by executive
ommittee members, as follows:
. General comments on management of carotid athero-
sclerosis (Richard P. Cambria, MD, SVS President);
. Clinical decision making in asymptomatic patients
(John J. Ricotta, MD, SVS Secretary);
. Real-world results of CEA vs CAS (Robert Zwolak,
MD, immediate Past President, SVS);
. Randomized trial data of CEA vs CAS (Peter Gloviczki,
MD, SVS President-Elect);
. Vascular surgeons as leaders in CAS (Daniel Clair, MD,
Chairman, Department of Vascular Surgery, Cleveland
Clinic Foundation); and
. Cost implications of changing the NCD (Julie Freis-
chlag, MD, SVS Vice-President).
Although theMEDCACwas not convened to consider
change in the NCD for CAS, virtually all speakers and
rofessional society representatives voiced position state-
ents on this issue. Predictably, interventional societies
eg, Society of Interventional Radiology and Society for
ardiac Angiography and Intervention) spoke in favor of
xpanded coverage for CAS, whereas professional societies
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SVS, American Association of Neurological Surgeons, and
the American Academy of Neurology, voiced position
statements against expansion for CAS, in particular in
asymptomatic patients. The SVS position is, of course,
clearly articulated in the recently published updated SVS
practice guidelines referable to extracranial cerebrovascular
disease.1 For purposes of the MEDCAC, the SVS position
on the NCD for CAS was also outlined in a cover letter to
the CMS coverage group (available on the CMSWeb site).
The MEDCAC process involved the panel’s review of
the available literature and the submitted written com-
ments and testimony of the invited speakers, who were then
specifically questioned for a period of time by the panel.
The panel clearly gave major consideration to the invited
speakers, and accordingly, it is appropriate to summarize
briefly the presentations of these invited speakers (see Dis-
cussion).
The SVS believes that its members and readers of the
Journal of Vascular Surgery should be adequately informed
about the latest evidence referable to the management of
carotid atherosclerosis. Indeed, at a special retreat of its
research council, the SVS recently identified management
of asymptomatic carotid atherosclerosis as its number 1
clinical research priority. The seven research questions con-
sidered by the MEDCAC are detailed individually in what
follows, along with the SVS reply and the MEDCAC panel
voting results to the individual questions.
Question 1: How confident are you that there is
adequate evidence to determine if persons in the Medi-
care population who are asymptomatic for carotid ath-
erosclerosis can be identified as being at high risk for
stroke in either cerebral hemisphere?
THE SVS HAS A HIGH (SCORE 4) LEVEL OF CONFIDENCE
THAT SUCH PATIENTS CAN BE IDENTIFIED, BASED ON THE
AVAILABLE NATURAL HISTORY AND CLINICAL TRIAL DATA. SUCH
IDENTIFICATION AT PRESENT IS LARGELY A FUNCTION OF DE-
GREE OF STENOSIS, WHICH IS A REASONABLE, IF IMPERFECT,
SURROGATE FOR HIGH RISK. THE SVS AGREES THAT FURTHER
RESEARCH IN THIS AREA IS NEEDED.
The degree of carotid bifurcation stenosis has been the
most significant factor in determining whether symptom-
atic and asymptomatic patients were both at risk of subse-
quent neurologic events. Stenosis was initially determined
exclusively by angiography, but as noninvasive techniques
improved, these methods supplanted angiography as the
primary means for quantifying stenosis. Observational data
from a number of sources have correlated the degree of
stenosis and stroke risk in asymptomatic patients. In several
reports on longitudinal studies of patients with asymptom-
atic cervical bruits, Chambers and Norris2 correlated both
the degree of stenosis and the occurrence of plaque pro-
gression with stroke risk. Roederer et al3 monitored pa-
tients with cervical bruits and documented a high incidence
of symptoms associated with plaque progression (35% at 6
months; 48% at 1 year). These and other observational data
were subsequently confirmed by three prospective random- 9zed trials that have shown the utility of stenosis as a
redictor of increased stroke risk that can be reduced by
EA:
● The Veterans Affairs (VA) trial4 randomized 444
asymptomatic patients with hemodynamically signifi-
cant stenosis by noninvasive testing and a50% angio-
graphic stenosis to CEA or medical therapy. There was
a 2.5-fold reduction (8% vs 20.6%) in ipsilateral isch-
emic events and a twofold reduction in ipsilateral
stroke (4.7% vs 9.4%) over a mean 48-month follow-
up.
● The Asymptomatic Carotid Atherosclerosis Study
(ACAS) trial5 randomized 1662 asymptomatic pa-
tients with60% carotid stenosis between surgery and
medical therapy and, again, found a twofold reduction
in stroke for CEA vs medical therapy (5.1% vs 11%).
● The largest and most recent trial, the Asymptomatic
Carotid Surgery Trial (ACST),6 randomized 3120
asymptomatic patients, with strikingly similar benefits
for CEA over medical therapy (6.4% vs 11.8%) at 5
years. This study was able to identify an increased risk
of stroke in patients with “severe” (80%-99%) stenoses
compared with (60%-79%) stenosis.
Stenosis has the benefit of being easily and reliably
easured by several techniques, but it is a relatively non-
pecific indicator of stroke risk because in all of these trials,
he annual stroke risk was modest and most patients in the
edical arm did not develop neurologic symptoms. Efforts
o characterize a group of patients, or a type of lesion,
ssociated with an increased risk of stroke have included
valuation of plaque character, overall symptom status, and
vidence of silent embolization to refine the definition of a
stroke-prone” lesion. Moore et al7 documented surface
lceration as an independent risk factor for stroke in asymp-
omatic patients. In 72 asymptomatic patients with ulcer-
tions and 50% stenosis, they reported a 12.5% annual
ncidence of symptoms in large or complex ulcers vs 0.4%
early incidence when only “minor” ulceration was present.
Surface ulceration and thrombus was associated with
he presence of symptoms in 241 plaques (170 asymptom-
tic and 71 symptomatic) taken from patients enrolled in
heNorth American Symptomatic Carotid Endarterectomy
rial (NASCET) and ACAS trials.8 Echolucent and heter-
geneous plaque, as characterized by high-resolution ultra-
ound imaging, has been found more often in lesions that
re symptomatic compared with asymptomatic steno-
es.9,10 Plaque features, such as intraplaque hemorrhage
dentified on magnetic resonance imaging (MRI), lipid
ontent, and thin or ruptured fibrous cap, have also been
orrelated with subsequent development of symptoms in
symptomatic patients.11 A refined protocol of further
lague imaging or transcranial Doppler (TCD) monitoring
or microembolization, or both, may ultimately prove ap-
ropriate; further research and cost considerations will be
aramount.
In a study of 821 asymptomatic patients with 60% to
9% carotid stenosis, Kakkos et al12 identified asymptom-
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July 2012e4 Cambriaatic ipsilateral cortical infarcts in 17.8%. Patients with
asymptomatic ipsilateral cortical infarctions had double the
annual neurologic event rate (4.8% vs 2.4%), irrespective of
whether the stenosis was “moderate” (60%-79%) or “se-
vere” (80%-99%). The Asymptomatic Carotid Stenosis and
Risk of Stroke (ASCRS) trial10 monitored 1121 patients
with asymptomatic stenoses of 50% to 99% for an average of
48 months. Information on the degree of stenosis, clinical
conditions, and plaque character was obtained at entry.
Factors associated with an increased risk of ipsilateral isch-
emic events, in addition to degree of stenosis, included age,
hypertension, smoking 10 packs/year, renal insuffi-
ciency, contralateral transient ischemic attack (TIA),
plaque size, and plaque character. Cerebrovascular risk
scores were developed from these data that allowed the
investigators to define four categories of 5-year stroke risk
that varied from 5% to 20%.10 These data remain to be
validated by further studies; yet in the ASCRS study, the
overall event (TIA/stroke) rates in patients who harbored
asymptomatic stenoses of a degree wherein CEA would be
recommended by SVS guidelines was an impressive 10% at
just 3 years of follow-up.
At present, stenosis remains the sole plaque feature that
can be easily, reliably, and economically measured in clini-
cal practice. It is a marker of increased stroke risk, particu-
larly if plaque progression is seen over time. Ulceration,
plaque character and size, and evidence of ipsilateral corti-
cal infarction are also likely factors that increase the risk of
neurologic symptoms. However, further research is needed
to determine the relative importance of these factors and
whether they can be reproducibly used as part of an algo-
rithm to reliably identify patients who can be treated with
medical therapy alone. At present, Level 1 data from
5000 patients show that selecting patients for interven-
tion by degree of stenosis alone, although not ideal, is
sufficient to significantly reduce stroke risk with CEA.
Although BMT has been shown to reduce stroke risk in
the last decade,13,14 it does not follow that this has obviated
the additional benefit of CEA demonstrated by multiple
controlled trials. In particular, the 10-year data from the
ACST trial demonstrated that the net gain in stroke pro-
tection for CEA vs BMT, although greater in patients not
taking statin mediations, was still highly significant, even
in those who were receiving such medical therapy.15 Given
that one-third of strokes occur without warning, and one-
half of TIAs are ignored or misdiagnosed, coupled with the
economic, physical, and psychologic impact of stroke, there
remains a continued need to treat carotid stenosis in a
presymptomatic state. It would be ideal to have more
reliable discriminating markers of stroke risk in the future.
Identification of risk factors in addition to the degree of
stenosis that can be widely and reliably measured would be
an important part of future investigation into the proper
therapy of asymptomatic carotid bifurcation disease.
MEDCAC panel voting results. Six of 13 voting
members recorded a level 4 vote (ie, identical to the SVS
position and between intermediate and high confidence).
One “1” vote dropped the overall average score to 3.15; ohus, the MEDCAC panel had a net intermediate level of
onfidence in question 1.
Question 2: How confident are you that there is
dequate evidence to determine if persons in the Medi-
are population, who are considering carotid revascu-
arization, can be identified as being at high risk for
dverse events from CEA?
THE SVS HAS A HIGH (SCORE 4) LEVEL OF CONFIDENCE
HAT PATIENTS AT HIGH RISK FOR ADVERSE EVENTS FROM CEA
AN BE IDENTIFIED.
The prospective randomized trials comparing CEA and
MT5,6,15,16 excluded a number of patients who are often
reated by CEA. In many cases, the reasons for lack of
ligibility were based on the need to maximize follow-up or
o exclude patients who might have other sources of stroke
r unstable medical conditions. Although it is true that the
erioperative mortality was lower (0.1%-0.6% vs 1.4%-
.75%) in the randomized trials than in real-world Medi-
are beneficiaries,17 these results were clearly within thresh-
lds of the AHA recommendations.18 Therefore, although
t made sense to study CAS in patients in whom the benefit
f CEA had not been proved by Level 1 data, it was not
ecessarily accurate to characterize these patients as “high
isk,” in particular with respect to patient age thresholds for
rial inclusion.
The definition of “high medical risk” is imprecise and
ot supported by robust data. Multiple single-center stud-
es demonstrated that about one-third of CEA patients
ould have been eligible for “high-risk” CAS studies and
hat there was no difference in outcomes in these patients
nd in those who did not have these “high-risk” character-
stics.19-21 Stroke and death rates in single-center reports of
high-risk” patients range from 1.6% to 3.6%. Outcomes
rom the National Surgical Quality Improvement Program
NSQIP) database were similar.22 In the latter study, 30%
f 3949 CEAs in the NSQIP database met “high risk,” as
efined in criterion from the Stenting and Angioplasty with
rotection in Patients at High Risk for Endarterectomy
SAPPHIRE). Overall stroke and death rates in this group
ere 2.2%, and again, there were no differences between
he “high-risk” and “normal-risk” patients.
Two factors do seem to be associated with increased
omplication rates after CEA: symptomatic cardiac disease
nd renal failure. Every major study of CEA has demon-
trated that the major non-neurologic source of morbidity
nd mortality with CEA is cardiac. The most recent ran-
omized trial data comparing CAS and CEA show that
EA is associated with an increased incidence of cardiac
vents and a decreased risk of stroke and death compared
ith CAS.23-25
It is intuitively logical that patient with severe ventric-
lar dysfunction, active coronary ischemia, and uncompen-
ated congestive heart failure would constitute a medical
igh-risk group. Patients, particularly those who are asymp-
omatic neurologically, should be evaluated for cardiac
schemia, and every patient’s cardiac condition should be
ptimally treated before carotid intervention. In general,
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on preoperative cardiac evaluation in this regard; clinical
profiling, patient functional status, and the consideration of
CEA as low-risk surgery are all considered. Renal insuffi-
ciency is somewhat less import, although there is evidence
that it does increase the risk of both CEA and CAS.26 This
is therefore an important factor to consider, particularly in
the neurologically asymptomatic patient. Alternatively, the
large Asymptomatic Carotid Stenosis and Risk of Stroke
(ACSRS) study identified renal insufficiency as a risk factor
for neurologic events in patients with asymptomatic severe
carotid stenosis, thereby making the overall impact of renal
disease on clinical decision making problematic (see ques-
tion 1, above). Severe chronic lung disease may increase
risks of general anesthesia, but this is uncommonly encoun-
tered in clinical practice, and when CEA is indicated, such
patients are often managed without a general anesthetic,
namely, with a cervical plexus block.
Definition of “anatomic high risk” is generally more
straightforward. The SVS, in a prior position statement to
CMS (March 2, 2008—CAG00085R6), favored reim-
bursement for CAS in circumstances of anatomic high risk
as defined by the SVS. These are situations in which local
factors would increase risks of cranial nerve injury or wound
infection, such as fibrosis or scarring of the neck, or lesions
that cannot be readily reached through a standard cervical
incision. Such conditions include a hostile neck, with ex-
tensive scarring from radiation or prior surgery, presence of
a stoma in the neck, or a lesion that extends above the level
of the second cervical vertebra or below the clavicle.1 It is
important to note, however, that the mere history of radi-
ation or neck surgery does not constitute “anatomic high
risk,” and there have been multiple reports of CEA with
excellent results in patients if fibrosis and scarring are not
severe.27-29 Furthermore, lesions in many patients associ-
ated with prior endarterectomy are fibrous in nature and are
likely to remain asymptomatic for long periods of time.30
Data on the effect of contralateral carotid occlusion are
mixed. Although NASCET identified patients with con-
tralateral carotid occlusion as having increased risk of stroke
after intervention,31 many single-center series, where oper-
ative technique and indications for shunt use are more
standardized, report excellent results with CEA in the face
of contralateral occlusion.32-34
In summary, the exclusion criterion from ACAS and
NASCET do not of themselves define a “high-risk” group
for CEA.Data sets from single-center series and theNSQIP
demonstrate that excellent results with CEA can be
achieved in carefully selected patients despite the presence
of “high-risk” markers. Careful selection is particularly
important in asymptomatic patients and is likely the reason
that these reported series18-22 contrast favorably with the
results of CEA in the SAPPHIRE trial,35 where the com-
bined risk of stroke and death was 7.3% even though 70% of
patients in that trial were asymptomatic.
The major medical conditions that increase the risk of
complications associated with CEA include active coronary
disease, severe left ventricular dysfunction, and uncompen- tated congestive heart failure. These conditions, as well as
ypertension and diabetes, should be optimally managed in
eurologically symptomatic patients before surgery. This is
lmost always possible within a few days. Asymptomatic
atients with these conditions should not be subjected to
ny intervention because the long-term benefit of interven-
ion is low. Occult coronary ischemia should be identified
nd treated before surgery for asymptomatic carotid steno-
is to minimize cardiac risk, and significant, untreatable
oronary disease should interdict intervention for an
symptomatic carotid stenosis. Anatomic high-risk patients
ho are neurologically symptomatic should be evaluated
or CAS, whereas the decision between CAS and medical
anagement for asymptomatic patients at anatomic high
isk for CEA remains unresolved at present.
MEDCAC panel voting results. Eight of 13 voting
embers recorded a level 4 vote, identical to the SVS
osition. The panel average score was 3.56, indicating a
igher than intermediate level of confidence in question 2.
Question 3: For persons with symptomatic carotid
therosclerosis and carotid narrowing (>50% by an-
iography or >70% by ultrasound imaging) who are
ot generally considered at high risk for adverse events
rom CEA:
. How confident are you that there is adequate evi-
dence to determine whether or not either CAS or
CEA is the favored treatment strategy, compared
with BMT alone, to decrease stroke or death in the
Medicare population?
. If there is at least intermediate confidence (score
>2.5), how confident are you that
i. CAS is the favored treatment strategy in this
population?
ii. CEA is the favored treatment strategy in this
population?
iii. BMT alone is the favored treatment strategy in
this population?
THE SVS IS HIGHLY CONFIDENT (SCORE 5) THAT CEA IS
HE FAVORED TREATMENT STRATEGY IN SUCH PATIENTS.
The data conclusively support use of CEA as the pri-
ary treatment in such patients, and this is reflected in
everal practice guidelines (including that of SVS) pub-
ished in 2011.1 The NASCET and European Carotid
ymptomatic Trial (ECST) demonstrated the benefit of
EA in neurologically symptomatic patients with carotid
tenosis 50%.36,37 There was a 7% incidence of fatal and
onfatal strokes in the surgical group in contrast to 24% in
he medically treated group (P  .001) in patients with
70% stenosis. This represented an absolute risk reduction
f 17% in surgically treated patients over the ensuing 18
onths. The mortality rate among the medically treated
roup was 12% in contrast to 5% for the surgically treated
roup (P  .01), with a 58% mortality risk reduction in
avor of CEA.
Subsequent analysis of NASCET data demonstrated
he beneficial effect of CEA for patients with 50% to 69%
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July 2012e6 Cambriastenosis but not for those with 50% stenosis.36 Results
from ECST corroborated these data, even though a slightly
different method was used for measuring the degree of
stenosis. ECST demonstrated that the perioperative (for
CEA) risk of stroke and death was 7.5%, yet CEA still
resulted in a significant reduction in subsequent stroke at
the 3-year interval (P .0001). This, in turn, was related to
a 26.5% stroke risk in the medical treatment with CEA,
resulting in an absolute risk reduction of 14.9%.37
The results of these early trials firmly established CEA
as the treatment of choice for patients with severe symp-
tomatic carotid stenosis and are now widely accepted
throughout the medical community. It is to be emphasized
that procedural complications of CEA in these trials were
roughly twofold increased compared to CREST. This was a
grade 1 recommendation with a level of evidence B in the
SVS updated guidelines.1
More recently, data from CREST and International
Carotid Stenting Study (ICSS) have been further scruti-
nized.23,38 In CREST at 30 days, the rate of stroke was
significantly higher with stenting, at 4.1% vs 2.3% with
surgery (hazard ratio [HR], 1.9; P  .005), when all
patients were considered, with such differences being more
pronounced in symptomatic patients (CAS 6.0% 0.9% vs
CEA 3.2%  0.7%; HR, 1.9, P  .02).25 CEA demon-
strated HRs of 1.74 ipsilaterally and 1.89 for any proce-
dural stroke or death, favoring CEA over CAS.23,25 In
ICSS, risk of stroke, death, or procedural myocardial infarc-
tion was higher in the stenting group than in the CEA
group, with a 30-day risk of 7.7% vs 4.0%, with a risk ratio
(RR) of 1.83 (P  .003) and a risk difference of 3.3%.38
These two large prospective randomized studies favored
CEA over CAS for treatment of symptomatic patients.
This led internationally respected neurologists, Davis
and Donnan, to conclude in an accompanying editorial to
the CREST publication that, “from this data, surgery is the
treatment of choice, at least for patients with symptomatic
carotid stenosis. Namely, carotid artery stenting is associ-
ated with a higher periprocedural risk of stroke or death, a
difference that was still significant at 4 years.”23 Similarly, in
a commentary accompanying publication of the ICSS re-
sults in The Lancet, Peter M. Rothwell, MD,39 a noted
Oxford neurologist and participant in multiple carotid dis-
ease trials, noted an excess of acute ischemic embolic lesions
on diffusion-weighted MRI after CAS (46%) compared
with CEA (14%; P  .0001). Thus, enforcing the conclu-
sion from the ICSS40 manuscript that “Short-term results
from this randomized control trial show that CEA is safer
than carotid stenting for treatment of patients with symp-
tomatic carotid artery stenosis.”38,41
The most recent meta-analysis of all randomized trials
conducted at the Health Policy Research Institute of Mayo
Clinic compared CEA with CAS and included some 7484
patients, 80% of whom were treated for symptomatic ca-
rotid stenosis. Compared with CEA, CAS was associated
with an increased risk of any stroke (RR, 1.40; 95% CI,
1.06-1.99).24 When the analysis was restricted to the two
most recent trials with better study methodology and more dontemporary techniques, there was a significant increase in
oth stroke (RR, 1.82; 95% confidence interval [CI], 1.35-
.45) and periprocedural mortality (RR, 2.53; 95% CI,
.27-5.08) for CAS vs CEA; CAS had a nonsignificant
eduction in periprocedural myocardial infarction com-
ared with CEA.
The European trials were often criticized for using less
xperienced carotid interventionists as well as not univer-
ally using cerebral protection devices.41,42 Martin M.
rown, Principal Investigator of ICSS, and Warner Hacke,
rincipal Investigator of the Stent-Supported Percutaneous
ngioplasty of the Carotid Artery versus Endarterectomy
SPACE) trial, brought up a very interesting question,
hen asked about the Endarterectomy Versus Angioplasty
n Patients With Symptomatic Severe Carotid Stenosis
EVA-3S), SPACE, and ICSS results, by stating that,
These trials were not designed to test the very best inter-
ventionists against the very best surgeons. Instead, they
answered the question more relevant to patients and
health service providers, viz. are the results equivalent for
the average interventionist that treats the patient com-
pared to the average surgeon. The trials have convincingly
shown that on average, carotid surgeons do revasculariza-
tions in symptomatic patients better than do intervention-
ists. This does not mean that the best interventionists
could not do revascularization more safely than the less
good surgeon, but it does make it unlikely that the best
interventionists do the procedure more safely than the
best surgeon.
Despite the often-heard criticism about the level of
nterventionalist skill in the European trials, the data indi-
ate that the stroke/death rate in ICSS (7.4%) for CAS is
ot statistically different than that for symptomatic patients
reated with CAS in CREST (6.0%).
The data on upfront stroke/death risk apparently indi-
ate a minimum of a twofold-increased risk for such com-
lication for CAS compared with CEA. These data are
ntuitively logical given the nature of plaque pathology
ssociated with symptomatic carotid stenosis; to wit, such
atients are likely to have intraplaque hemorrhage and
ther features of unstable plaque.
In conclusion, the data indicate that for symptomatic
atients, CEA is the favored treatment strategy in virtually
ll populations. CAS should be reserved as an alternative
nly for those patients who are anatomically unsuitable for
EA or who have significant physiologic comorbidities that
ake it impossible for them to undergo a CEA under
ervical block anesthesia. In addition, BMT alone would
nly be a logical treatment alternative in patients with
omorbid conditions expected to limit their longevity to
1 year.
Although the SVS knows of no data to indicate that
pecific sex or racial/ethnic background would have a
aterial effect on the above conclusions, a particular con-
ideration of patient age is in order. In this consideration,
aterial discussed also in question 4 is pertinent. An abun-
ance of literature, including CREST,23 has associated
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pared with CEA. In virtually all CAS trials, the highest
complication rates were in symptomatic octogenarians, of-
ten reaching levels that most vascular surgeons would con-
sider unacceptable. The inflection point in CREST for
significantly worse outcomes for CAS occurred at about age
75 years. There are also data available indicating unaccept-
able complication rates for CAS when performed within 14
days of neurologic events. Analysis of the combined Ca-
rotid Acculink/Accunet Post-Approval Trial to Uncover
Unanticipated or Rare Events (CAPTURE) and Em-
boshield and Xact Post Approval Carotid Stent Trial (EX-
ACT) registries revealed stroke/death rates for CAS ap-
proaching 10% in this setting; again, this is consistent with
the nature of the pathology in recently symptomatic
plaques. In older and recently symptomatic patients, CEA
is much preferred to CAS.
MEDCAC panel voting results. Six of 13 voting
members recorded a level 4 or 5 vote, swinging the overall
panel average to 3.46 (ie, in between intermediate and high
confidence for this question). As noted above, in the pres-
ence of at least intermediate confidence to the principle
research question, derivative questions were then voted on.
There was low confidence (score, 1.85) that CAS and
nearly high confidence (score, 3.62) that CEA was the
favored treatment in symptomatic patients. Similarly, there
was low confidence (score, 1.69) that BMTwas the favored
treatment in these patients.
Question 4: For persons with asymptomatic carotid
atherosclerosis (>60% by angiography or >70% by
ultrasound imaging) who are not generally considered
at high risk for adverse events from CEA:
a. How confident are you that there is adequate evi-
dence to determine whether or not either CAS or
CEA is the favored treatment strategy, as compared
to BMT alone, to decrease stroke or death in the
Medicare population?
b. If there is at least intermediate confidence (score
>2.5), how confident are you that
i. CAS is the favored treatment strategy in this
population?
ii. CEA is the favored treatment strategy in this
population?
iii. BMT alone is the favored treatment strategy in
this population?
SVS IS HIGHLY CONFIDENT (SCORE 5) THAT FOR PERSONS
WITH ASYMPTOMATIC, SEVERE (60% BY ULTRASOUND OR
OTHER IMAGINING STUDIES BY NASCET CRITERIA) CAROTID
STENOSIS, THERE IS ADEQUATE EVIDENCE IN THE FORM OF
LEVEL 1 DATA FROM LARGE, RANDOMIZED TRIALS SUPPORTING
CEA AS AN EFFECTIVE TREATMENT STRATEGY (COMPARED
WITH BMT) TO DECREASE STROKE OR DEATH IN THE MEDI-
CARE POPULATION. THE SUPPORTING EVIDENCE COMES IN THE
FORM OF (1) DATA FROM WELL-CONDUCTED, LARGE, RANDOM-
IZED TRIALS AND (2) AVAILABLE NATURAL HISTORY DATA OF
STROKE RISK RELATED TO HIGH-GRADE, ASYMPTOMATIC CA-
ROTID STENOSIS. wConsistent with not only the SVS updated practice
uidelines1 but also practice recommendations from at least
our other international practice guidelines published dur-
ng calendar year 2011,43-46 CEA is supported as an effec-
ive stroke-reduction strategy in appropriately selected pa-
ients with severe asymptomatic carotid stenosis. On the
asis of the available trial data, the designation of appropri-
te patients are those with an acceptable operative risk and
n anticipated life expectancy of minimum of 3 to 5 years
nd those with high-grade (60% NASCET criteria) ste-
osis, because this subgroup has been consistently identi-
ed as being at increased risk for stroke.
ATA SUPPORTING CEA AS THE FAVORED
REATMENT STRATEGY IN THIS
OPULATION
Three internationally recognized, randomized, pro-
pective studies have addressed question 4 with consistent
esults supporting CEA as the optimal treatment strategy
VS:
The VA study. The VA cooperative, asymptomatic,
arotid surgery study4 was conducted in Veterans Admin-
stration hospitals and, accordingly, limited to men. Its
riteria for entry were a50% (by angiography) asymptom-
tic stenosis, and 444 patients were randomized to CEA vs
vailable medical therapy, which at that point was 650 mg
cetylsalicylic acid. The study was published in 1993, and
he perioperative stroke/death rate after CEA was 4.3%.
he primary outcome measure was combined ipsilateral
eurologic event (TIA or stroke, or both) and death, which
ccurred in 8% of CEA patients vs 20.6% of the medically
reated cohort (RR reduction, 38%; P .0002). In consid-
ration of stroke alone, the respective figures (4.7% vs 9.4%)
ere insignificant related to the small study cohort. There
as no survival benefit to CEA related to an overall exces-
ive (10% yearly) mortality in the entire study cohort.
espite the small sample size and inclusion of patients with
moderate degree of stenosis, the data favored CEA as a
ore effective stroke-reducing strategy.
The ACAS study. The larger ACAS study (published
n 1995) was conducted at 39 North American community
nd academic centers, with 117 surgeons participating.5
CAS randomized 1662 patients with 60% stenosis
NASCET method, angiography mandated before CEA)
o CEA or medical therapy consisting of 325 mg acetylsal-
cylic acid and telephone-monitored risk factor reduction
ounseling. Study end points were any stroke/death, and
edian follow-up was 2.7 years. Aggregate 5-year stroke/
eath occurred in 5.1% of CEA patients vs 11.0% of the
edically treated cohort (RR reduction, 53%; P  .004).
avorable treatment effect of CEA was more pronounced
n men. Overall perioperative stroke/death was 2.3% in
EA patients, half of which was referable to the mandated
rteriography. Accordingly, the benefit of CEA would have
een enhanced by elimination of catheter angiography, a
eality of clinical practice over time. One large study docu-
ented that 10% of CEA patients were being evaluated
ith invasive angiography by the year 2000.47
a
i
(
i
a
c
p
C
c
s
c
o
c
s
A
r
s
i
i
s
p
S
r
c
a
a
A
A
p
i
c
n
p
s
y
f
d
i
t
a
p
d
r
v
a
s
p
a
t
B
A
1
JOURNAL OF VASCULAR SURGERY
July 2012e8 CambriaACST trial. This was the most recent and largest
randomized, prospective study of CEA vs BMT, which was
conducted in 30 countries and at 128 hospitals. ACST
randomized 3120 patients beginning in 1993, and the final
patients were enrolled in 2003. The initial publication of
the actuarial 5-year stroke risk showed a highly significant
reduction in ipsilateral disabling strokes and in all strokes in
patients treated with CEA vs BMT (RR, 6.4% vs 11.8%; net
gain, 5.4%; P  .0001).6 Important to point out with
respect to the data analysis is that nearly 50% of patients
actually completed 5 years of follow-up at the time that the
study was initially published in 2004. Although analysis was
on an intention-to-treat basis, the crossover rate from the
medical arm to CEA was 17% during the follow-up period.
Stroke and death in the surgically treated patients was 2.8%
within 30 days, and similar to many other large trials,
myocardial infarction after CEA occurred in 1%. The data
indicated that clinical decision making seemed appropriate,
because the annual overall mortality (identical to ACAS) of
study participants was 3.5% per year.
With respect to patient longevity, the curves of antici-
pated benefit of treatment crossed at 2 years, which was
the interval required for the BMT group to “catch up” to
the upfront morbidity of surgery. The data indicate that the
annual risk of stroke in patients with BMT was in the 2%
range, essentially doubled the rate of the surgically treated
cohort. Long-term data from the ASCT trial, out to 10
years, have now been published.15 These data indicate that
the nearly 6% gain in stroke prevention of the surgically
treated cohort was sustained even out to 10 years of follow-
up. Net gain in the ASCT trial was equivalent for men and
woman, and a particular analysis of the late follow-up data
in this trial has direct bearing on the question of the
adequacy of BMT alone. In the latter years of the trial,
lipid-lowering therapy and antiplatelet therapy were used in
80% of patients. Although the proportionate gain of CEA
vs medical therapy was larger in patients not receiving
lipid-lowering therapy before stroke, the net gain at both 5
and 10 years remained highly significant for the surgically
treated patients vs the medically treated cohort even on those
on lipid-lowering therapy. To quote the ACST investiga-
tors, “modern statin regimens can reduce occlusive vascular
events by more than a third, yet patients with tight carotid
stenosis cannot have the risk from it completely abolished
by medical treatment alone.”15
It is unfair, in a sense, to compare the protective effect
of CEA in stroke prevention with that of CAS because CAS
has not been adequately evaluated in this regard. At the
moment, there are no data supporting CAS as an effective
stroke-preventive strategy in asymptomatic patients. In-
deed, a recently published Medicare database study found
overall mortality for CAS was 1.9% among nearly 25,000
CAS procedures performed in Medicare beneficiaries be-
tween 2005 and 2007.48 SVS clinical practice guidelines
state that CEA is the preferred treatment in these patients,
and the ACC/AHA multispecialty guidelines indicate, has
a Class 2B recommendation, that “prophylactic CASmight
be considered in highly selected patients with asymptom-tic carotid stenosis, but its effectiveness compared to med-
cal therapy alone in this situation is not well established”
Level of Evidence B.)1,43 International practice guidelines
ndicate that CAS should only be performed in asymptom-
tic patients in the context of well-conducted prospective
linical trials.45,46 Accordingly, when intervention is appro-
riate in asymptomatic carotid stenosis, the SVS supports
EA as the preferred therapy.
With respect to concurrent BMT in patients who are
andidates for intervention for high-grade asymptomatic
tenosis, the current guideline with respect to processes of
are for CEA indicates that all patients who are under
bservation for asymptomatic carotid stenosis, and espe-
ially patients who are being potentially treated with CEA,
hould be on combined antiplatelet and statin therapy.1,49
prior Medicare database study50 and a regional quality
egistry51 indicate a significant reduction in perioperative
troke/death in patients treated with antiplatelet therapy.
Other studies have documented a significant reduction
n perioperative events for patients treated with statin med-
cation.52 Furthermore, at least one report has correlated a
ignificant reduction in the risk of restenosis after CEA in
atients being treated with lipid-lowering therapy.53 The
VS knows of no reliable data suggesting that individual
acial or ethnic backgrounds have variable results with
omplications from CEA or long-term stroke protection
fter CEA. Furthermore, the above-cited trial results are
pplicable to the Medicare population because 15% of
CAS patients were aged 60 years, and two-thirds of
CST patients were aged 65 years at enrollment.
A particular comment referable to patient age is appro-
riate. A substantial body of literature has indicated that
ncreasing patient age is correlated with significantly in-
reased risks of perioperative morbid events after CAS but
ot after CEA. The roll-in phase of CREST noted a 12%
eriprocedural risk of stroke and death in octogenarians,
ignificantly higher than the 5% risk in those aged 80
ears.54 Many other single-center reports, including those
rom acknowledged experts in CAS, have reported similar
ata. The CREST trial investigators reported a significant
nteraction with patient age and the differential complica-
ion rate of CAS vs endarterectomy with the infection point
t age 75 years.23 However, the converse with respect to
atient age and anticipated complications of CEA appears
isproven by the best available current evidence. A recently
eportedNSQIP study that specifically focused on high-risk
ariables documented an overall 30-day (nurse-reviewer
djudicated) stroke/death rate of 2.2% after CEA.22 In this
tudy, 19% of some 3949 patients treated with CEA in
rivate sector hospitals were aged80 years, but perioper-
tive complications were no different in octogenarians vs
hose aged 80 years.
MT ALONE FOR HIGH-GRADE
SYMPTOMATIC STENOSIS
. The SVS supports the position that future large-scale
prospective studies of stroke prevention strategies in
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include an optimal medical therapy treatment arm.
2. The SVS supports the position that all patients under
observation with carotid stenosis or being considered
for interventional therapy for carotid stenosis should
also be treated with optimal medical therapy, currently
consisting of antiplatelet therapy and lipid-lowering
therapy.1
3. The SVS agrees that future studies to stratify patients
with asymptomatic stenosis into those at high risk for
stroke are needed, but at the current time, degree of
stenosis is the best available surrogate for such clinical
decision making (see also response to question 1). An
abundance of literature, including the most recently
conducted prospective studies in patients with asymp-
tomatic carotid stenosis, consistently identifies degree of
stenosis as the best predictor of stroke risk.2,10,56
4. The contention that modern medical therapy is ade-
quate treatment to control or prevent stroke (or both)
from asymptomatic high-grade carotid stenosis is
unsubstantiated.
A comment on the flawed literature making this claim is
in order.13 In assessing stroke risk of asymptomatic carotid
stenosis, most clinicians have used data from the NASCET
study (specifically, those examining the fate of a high-grade
asymptomatic stenosis contralateral to the index artery for
entry into the trial),56 the original studies of Chambers and
Norris,2 and more recently, the medically treated patients
in the ACST trial and the ACSRS prospective study of
asymptomatic carotid stenosis.6,10,15,55
These studies in aggregate indicated that the annual
risk of unheralded stroke from high-grade asymptomatic
stenosis was at least 2% per year (the event rate was doubled
if TIA was included) and also showed that the first neuro-
logic event was as likely (or even more likely) to be stroke
rather than a TIA. There is little doubt thatmodernmedical
therapy has had an important impact on the overall risk of
stroke, but the contention that it constitutes effective
stroke prevention for patients with high-grade carotid ste-
nosis is unproved. A widely quoted 2009 meta-analysis
concluded that modern drug therapy alone is now the best
prevention for stroke in such patients.13 This meta-analysis
included data from two modestly sized prospective stud-
ies57,58 and one large prospective study.56 This meta-
analysis claimed that the annual risk of stroke of asymp-
tomatic “severe” carotid stenosis was now in the range of
0.5% per year.
The Second Manifestations of Arterial Disease
(SMART) study, however, included only 221 patients, 7%
of whom crossed over to surgical intervention during a
nearly 4-year follow-up interval and only half of the patients
had high-grade stenosis (NASCET, 70%-99%), wherein
prophylactic CEAwould typically be offered.57 TheOxford
vascular study58 concluded that the risk of ipsilateral stroke
was only 0.34% per year with BMT, but contained only 101
patients with 50% stenosis, and only 32 patients with a
70% to 99% stenosis, and three of these had a stroke. The svidence base to support the claim of BMT alone as ade-
uate treatment for asymptomatic carotid stenosis is seri-
usly flawed by the inclusion of many patients with only
oderate degrees of stenosis, such that they would not be
ffered an intervention by current guidelines.
In summary, the SVS is highly confident (score 5) that
EA is the favored therapy for appropriately selected
symptomatic patients. CAS is not adequately studied in
his patient population and none of five 2011 Practice
uidelines would support CAS in this setting. The conten-
ion that modern BMT in this setting would provide stroke
revention equivalent to CEA is unsubstantiated.
MEDCAC panel voting results. Nine of 13 voting
anel members voted level 1 or 2 scores, such that the
verall panel score was 2.15 (ie, low confidence that inter-
ention vs BMT is the best treatment strategy). Given the
ow confidence vote, the panel did not vote on the deriva-
ive questions.
Question 5: For persons with asymptomatic carotid
therosclerosis who are not generally considered at high
isk for stroke in either cerebral hemisphere:
. How confident are you that there is adequate
evidence to determine whether or not CAS or CEA
or BMT alone is the favored treatment strategy to
decrease stroke or death in the Medicare popula-
tion? SVS level of confidence: intermediate to high
(score 4)
. If there is at least intermediate confidence (score
>2.5), how confident are you that
i. CAS is the favored treatment strategy in this
population? SVS level of confidence: low
(score 1)
ii. CEA is the favored treatment strategy in this
population? SVS level of confidence: intermedi-
ate to high (score 4; see below)
iii. BMT alone is the favored treatment strategy in
this population? SVS level of confidence: low to
intermediate (score 2; see below)
THE ABOVE RESPONSES ASSUME THAT PATIENTS CONSID-
RED WOULD HAVE A DEGREE OF ASYMPTOMATIC CAROTID
TENOSIS WHERE CONSIDERATION FOR INTERVENTION BY CUR-
ENT SVS GUIDELINES (IE, 60% NASCET STENOSIS) PER-
AINS. THE SVS RECOMMENDS BMT FOR ASYMPTOMATIC
ATIENTS WITH LESSER DEGREES OF STENOSIS.
As discussed in detail earlier in the answer of question 1,
here continues to be a controversy over which patients
hould be considered at high or low risk of stroke with
arotid atherosclerosis. Level 1 evidence currently supports
he degree of stenosis as the most reliable indicator of in-
reased risk of stroke in patients with asymptomatic carotid
rtery atherosclerosis. Three randomized controlled trials
RCTs)4-6 that included 5223 patients with asymptomatic
arotid artery disease with internal carotid artery stenosis of
0% to 99% or 60% to 99%, confirmed the degree of stenosis
s a predictor of increased risk of stroke that could be
ffectively decreased by CEA. The absolute risk reduction is
mall, however, and in these RTCs, performed in the years
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risk of 0.5% to 1.0% vs BMT alone.
Considering the very low risk of stroke or death due to
mild or moderate asymptomatic carotid atherosclerosis
(60% carotid stenosis), there is an intermediate to high
level of confidence1 that asymptomatic patients who are not
generally considered at high risk of stroke due to mild
stenosis (60%) should receive BMT and should not un-
dergo intervention. There are no data that support CEA or
CAS in asymptomatic patients with 60% carotid stenosis.
The recommendation of the SVS carotid guidelines1 that
asymptomatic patients with stenosis60% diameter reduc-
tion should receive BMT is a Level 1 recommendation with
intermediate supporting evidence. This conservative strat-
egy is well supported, even in symptomatic patients with
data of the ECST, where BMT alone was recommended for
carotid stenosis of 0% to 29%. Results were inconclusive for
stenosis between 30% and 69%, with clear benefit of surgery
in those with a stenosis of 70% to 99%.37 In consideration
of asymptomatic severe carotid atherosclerosis (ie,
NASCET 60% to 99% stenosis), the level of evidence to
further stratify risk within this group is low.
As discussed earlier in this document, various factors in
addition to the degree of stenosis likely contribute to
increased risk of stroke. The ACSRS study found that
increasing stenosis, plaque characterization by ultrasound
imaging, history of contralateral TIA, and renal insuffi-
ciency were independent risk factors to predict stroke and
could distinguish a high-risk (4.7% per year risk of stroke)
from a low-risk (0.7%) group.10 Silent embolic infarcts,
contralateral carotid occlusion, plaque morphology, plaque
echolucency on ultrasound imaging and embolic signals on
transcranial Doppler ultrasound imaging, and MRI charac-
terization have all been proposed to predict a higher risk of
stroke in asymptomatic patients.12,59-63
Most importantly, no RCT to date has investigated the
effect of CAS, CEA, and BMT comparing low-stroke risk vs
high-stroke risk patients with severe (60% NASCET)
asymptomatic lesions. Although one would predict that
preocclusive lesions (80% to 99%), especially those that
progress during follow-up, have a higher risk than those
with a lesser stenosis, an observation documented by stud-
ies of Chambers and Norris,2 none of the RCTs could
provide evidence that patients with a lesser degree of ste-
nosis (50%-79%) were of lower risk to develop ipsilateral
stroke. As a consequence, the level of confidence to define
best therapy for low-risk patients with moderate to severe
carotid atherosclerosis remains low.
Patient age, sex, and racial/ethnic background.
The meta-analysis of Murad et al24 examined the effect
of age and sex on outcomes of patients who underwent
CAS or CEA. The meta-analysis concurred with other
data, including an individual patient-pooled analysis,63
CREST,23,64 and also the SPACE trial,41,42 that younger
patients did better with CAS than those aged 70 years.
These data support CEA over CAS as intervention in the
Medicare population. The meta-analysis failed to reveal any
significant treatment interactions based on sex. Howard et dl65 recently reported on the influence of sex in the CREST
rial that enrolled 872 women (34.9%). There was no
ifference in primary end points between different sexes
interaction P  .34). Although there was a trend to an
ncreased rate of periprocedural events in women after CAS
s CEA (6.8% vs 3.8%; P  .064), this difference was not
tatistically significant. In a recent review of a national
atabase, Rockman et al66 found that outcome among
omen for perioperative stroke favored CEA over CAS,
articularly in asymptomatic patients. No Level 1 data on
acial and ethnic background are currently available to
upport any of the treatment modalities preferentially in
hese subgroups.
Concurrent BMT. Results of BMT have greatly im-
roved in recent years and include complex risk factor
odification in addition to treatment of hyperlipidemia
nd therapy with statins, antihypertensive, and antiplatelet
edications.13,14 The CAS patients in CREST received
ombined antiplatelet therapy, including aspirin and clopi-
ogrel or ticlopidine, in the periprocedural period and for
t least 30 days after. Similar antiplatelet therapy was also
sed for patients who underwent CEA. New prospective,
ell-designed randomized studies should include not only
treatment arm with BMT, but also BMT in addition to
EA and CAS. Results of both CEA and CAS are expected
o improve in the future when best prevention and medical
reatment are used concurrent to interventions.
MEDCAC panel voting results. Of 13 voting panel
embers, there was wide discrepancy of opinion; six mem-
ers voted 1 or 2 (low confidence) and seven voted 4 or 5
high confidence), for a net score of 3.15. The derivative
uestions perhaps clarified the issue because the panel
oted low confidence (unanimous scores of 1 for both CEA
nd CAS) for interventions but voted 4.38 that BMT was
he favored approach.
Question 6a: What is the confidence relative to
dequate evidence to determine if carotid artery screen-
ng of asymptomatic persons decreases stroke or death?
Question 6b: If there is at least intermediate confi-
ence, how confident are you that carotid artery screen-
ng of asymptomatic persons decreases stroke or death?
THE SVS MAINTAINS A FAIRLY CONFIDENT POSITION
SCORE 4) THAT SCREENING ONLY AT-RISK POPULATIONS IS
ENEFICIAL.
Stroke is the third leading cause of death and is the
eading cause of disability in the United States and in the
estern world. Eighty percent of these strokes are isch-
mic, and many are secondary to carotid bifurcation ath-
rosclerosis. Unfortunately, only 15% of stroke victims have
warning TIA before the stroke, and waiting until symp-
oms occur is neither safe nor ethical because natural his-
ory studies of asymptomatic high-grade carotid stenosis
ndicate that the first event is likely to be a stroke rather than
TIA. Therefore, screening with duplex ultrasound imag-
ng to detect “stroke-prone” carotid bifurcation plaque and
dentify a high-risk patient likely to benefit from therapy is
esigned to reduce stroke risk.
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asymptomatic patients. Evaluation and treatment of pa-
tients who are asymptomatic is controversial. The benefit of
CEA for stenosis60%, although statistically significant in
large trials, is much less than for neurologically symptom-
atic individuals and rests on available natural history data
and the premise that intervention (ie, CEA) can be per-
formed with minimal morbidity and mortality.6
To date, there is no consensus on which patients should
undergo carotid screening for detection of carotid stenosis.
The American Society of Neuroimaging concluded that the
efficacy of screening would be related to the prevalence of
the disease in the screened populations.67 When the prev-
alence of stenosis was 20%, screening reduced the risk of
stroke in a cost-effective manner, with an intermediate
prevalence of between 5% and 20%, in some studies; how-
ever, the benefit was usually marginal and was lost if com-
plications of the intervention were5%. With a prevalence
of5%, screening has not been shown to reduce the risk of
stroke in a cost-effective manner and may be harmful.
Therefore, screening of the general population is not
justified. This is supported by multiple professional organi-
zations, including the Canadian Stroke Consortium,68 the
National Stroke Association,69 and the U.S. Preventive
Services Task Force.70 The American Stroke Association/
AHA Stroke Council71 concluded that highly selected pa-
tient populations may benefit, but screening of the general
population for asymptomatic carotid stenosis was unlikely
to be cost-effective and might have the potential adverse
effect of false-negative or false-positive results. Recently,
the SVS guidelines and a multispecialty expert consensus
document both recommended screening for asymptomatic
patients with a carotid bruit who are potential candidates
for carotid intervention and for those in whom coronary
artery bypass grafting (CABG) is planned.1,72
Screening patients with asymptomatic carotid
bruits. Ratchford et al73 found in a selected high-risk
subgroup of asymptomatic patients that if a bruit was heard,
25% had60% stenosis. The presence of a carotid bruit has
been shown to increase the absolute risk of stroke, MI, and
death.74 In general population-based studies, the preva-
lence of severe stenosis is not high enough to make bruit
alone an indication for carotid screening.With these facts in
mind, screening should be pursued only if a bruit is associ-
ated with other risk factors for stenosis and stroke in pa-
tients who have a low operative risk and are willing to
undergo carotid intervention. This is, of course, predicated
on the knowledge from randomized trials that CEA confers
superior long-term protection from stroke compared with
available medical therapy.6
High-risk stroke patients who may benefit from
screening for asymptomatic stenosis. Two studies have
identified specific groups of patients with a higher preva-
lence of significant carotid stenosis that may exceed30%.
Jacobowitz et al75 developed a model identifying patients
at high risk for50% asymptomatic carotid stenosis. These
included patients aged 60 years who had one or more of
the following risk factors: coronary artery disease (CAD),istory of hypertension, current smoking, and a first-degree
amily relative with a history of stroke. The prevalence of
arotid artery stenosis was only 2% if no risk factor was
resent, 6% with one risk factor, which increased to 14% for
wo risk factors, to 16% for three risk factors, and to 67% for
our risk factors.
Qureshi et al76 identified the following variables asso-
iated with 60% asymptomatic carotid stenosis: hyper-
holesterolemia (odds ratio [OR], 1.9), current smoking
OR, 2), CAD (OR, 2.4), and age 65 years (OR, 4.1).
atients undergoing coronary revascularization are another
roup with an increased prevalence of carotid stenosis of 2%
o 27%.77 Overall, the prevalence of carotid artery stenosis
mong patients undergoing CABG is higher than the gen-
ral population. In patients with symptomatic CAD and
ther risk factors, such as history of stroke or TIA, age65
ears, diabetes mellitus, left main coronary stenosis, periph-
ral arterial disease (PAD), carotid bruit, and previous
arotid operation, it is feasible that a subset of patients with
prevalence 20% can be identified who might benefit
rom carotid screening.78 The ACC/AHA and SVS guide-
ines both note that carotid screening before CABG is
robably indicated in the subset of patients aged65 years,
ith left main coronary stenosis, a history of smoking, a
istory of TIA/stroke or carotid bruit, and PAD.1,79 Sev-
ral studies have also suggested that the prevalence of
60% carotid artery stenosis among patients with symp-
omatic PAD is 20%, regardless of the patient’s age.
Overall, routine screening is not recommended to detect
linically asymptomatic carotid stenosis in the general pop-
lation or presence of a neck bruit alone without other risk
actors. Screening should be considered in patients with
ultiple risk factors that increase the incidence of disease as
ong as the patients are otherwise appropriate for carotid
ntervention if a significant stenosis is detected: patients
ith evidence of clinically significant peripheral vascular
isease, regardless of age, and patients aged65 years with
history of one or more of the following risk factors:
moking, CAD, or hypercholesterolemia. Carotid screen-
ng may be considered in patients before CABG, particu-
arly those aged 65 years who have left main disease or a
istory of peripheral vascular disease.1,79
MEDCAC panel voting results. Six of 13 voting
anel members expressed high confidence relative to ques-
ion 6a (ie, the available evidence), such that the overall
anel score was 3.54. Yet, the derivative question about
anel confidence in the value of screening scored poorly, at
.33. This may relate to the context of the question, which
onsidered only “asymptomatic persons.”
Question 7 (nonvoting question): What unmet re-
earch needs, specific to the following issues, are impor-
ant to consider and explore further?
. Should future stroke prevention trials
i. Be powered to evaluate only symptomatic or
asymptomatic patients?
ii. Be powered to draw conclusions regarding gen-der?
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diverse patient populations?
b. To help delineate those who require carotid revascu-
larization from those who do not, how should fu-
ture trials best utilize and validate for the Medicare
population the following tools to identify persons
with asymptomatic carotid atherosclerosis who are
at high risk for stroke?
i. Advanced imaging, such as 3D ultrasound, for
plaque morphology
ii. TCD for cerebral microembolization
iii. Preprocedure and postprocedure diffusion-
weighted MRI (DW-MRI) for silent infarcts
iv. Risk assessment tools and predictive stroke
models
FOR QUESTION 7.A.I., THE SVS MAINTAINS IT IS IMPERA-
TIVE THAT ALL FUTURE STROKE PREVENTION TRIALS SHOULD BE
POWERED TO EVALUATE SEPARATELY SYMPTOMATIC VS ASYMP-
TOMATIC PATIENTS.
The outcomes associated with the medical manage-
ment of symptomatic and asymptomatic carotid disease, as
documented in all currently available clinical trials, are so
vastly different that pooling data from asymptomatic and
symptomatic patients is highly likely to obscure important
outcome differences in the symptomatic patients while
exaggerating differences in asymptomatic patients. In the
NASCET (symptomatic trial), medical management of
70% to 99% symptomatic stenosis was associated with a
2-year stroke risk of 26%, whereas the medical management
of 50% to 69% symptomatic stenosis was associated with a
5-year stroke risk of 22%.16 In the ACAS (asymptomatic
trial), the medical management of asymptomatic 60%
stenosis was associated with a 5-year stroke risk of only
11%.5 Likewise, in the more recent ACST trial, medical
management of 70% asymptomatic stenosis was associ-
ated with a 5-year stroke risk of only 11.8%.6
THE SVS POSITION FOR QUESTION 7.A.II IS THAT GENDER
DIFFERENCES IN TREATMENT OUTCOMES ARE REAL BUT SEEM
INSUFFICIENT TO JUSTIFY POWERING STUDIES TO DETECT
GENDER-SPECIFIC DIFFERENCES IN RESPONSE TO TREATMENT.
Although in ACAS the RR reduction attributable to
carotid endarterectomy was 66% in men and only 17% in
women, this difference failed to reach statistical signifi-
cance. In ACAS, the risk of perioperative stroke or death
was 3.6% in women and 1.7% in men, but in many case
series published since ACAS, sex-related differences in op-
erative risk appear negligible. Large prospective database
instruments have shown that female sex is not associated
with increased risk for adverse outcomes after CEA.22,51 In
ACST, CEA was statistically significantly beneficial in both
men and women, although surgical risk in women re-
mained higher. Finally in the ECST (symptomatic trial),
perioperative stroke and death rates were higher in women
than in men (10.4% vs 5.8%), resulting in less benefit for
women and in a recommendation that the threshold degree
of stenosis warranting surgery be set higher for women than
for men.37 In these major randomized CEA vs medical panagement trials, sex-related treatment effects were real
ut did not negate the benefit of intervention for symptom-
tic or asymptomatic disease in men or women.
There are currently little data indicating a sex effect on
utcome in CAS, at least compared with CEA. In CREST,
he outcome difference attributable to sex was insignificant
P  .34).23,65 There are no data exploring sex effects in
edical management vs stenting trials.
THE SVS POSITION FOR QUESTION 7.A.III IS THAT THERE
RE NO DATA TO SUGGEST THAT STUDIES NEED TO BE POWERED
O DETECT OUTCOME DIFFERENCES IN MORE ETHNICALLY OR
ACIALLY DIVERSE POPULATIONS.
The prevalence of carotid disease varies among racial
roups, and the relative importance of carotid disease in
troke etiology varies tremendously among racial groups.
owever, there are no data suggesting that the ethnic or
acial profile of a population affects its responses to treat-
ent for symptomatic or asymptomatic carotid disease.
THE SVS POSITION FOR QUESTION 7.B.I IS THAT PLAQUE
ORPHOLOGY COULD EVENTUALLY BE PROVEN TO BE AS IM-
ORTANT AS THE DEGREE OF STENOSIS IN DETERMINING THE
ROGNOSIS OF ASYMPTOMATIC CAROTID LESIONS.
High-resolution 3D ultrasound imaging with computer-
nhanced plaque analyses can detect plaque characteristics
hat may be more important than the degree of stenosis in
etermining stroke risk in asymptomatic patients. The
CSRS trial offers the most compelling data in support of
laque morphologic features as prime determinants of
rognosis in asymptomatic patients.10 In this study, 1121
atients with asymptomatic 50% to 99% carotid stenoses
nderwent plaque characterization using a duplex ultra-
ound imaging protocol and then were monitored. This
rotocol showed that severity of stenosis, grayscale median
a measure of plaque echodensity), total plaque area, and
laque heterogeneity, as measured by the presence of non-
alcified discrete white areas, predicted a wide range of
linical outcomes.
On the basis of this work in asymptomatic patients, we
an identify a subset of patients with 80% stenosis with
mall, echodense, homogeneous plaques and no history of
ontralateral neurologic events, in whom the 5-year stroke
isk is only 1.9%. Conversely, in those asymptomatic pa-
ients with 80% stenosis with moderate to large, hetero-
eneous echolucent plaques and a history of contralateral
troke or TIA, the 5-year risk of stroke was 70%. Similarly,
n patients with 50% to 80% stenosis, these same criteria
dentify subgroups with 5-year stroke risks ranging from
.3% to 70.4%.10
These data offer compelling evidence that duplex
ltrasound-identifiable plaque characteristics other than ste-
osis are potentially important determinants of plaque behav-
or and, therefore, of prognosis in asymptomatic carotid
isease patients. Furthermore, significant emerging evi-
ence indicates that plaque morphology has a significant
ffect on stroke risk associated with CAS. Future clinical
rials should evaluate ultrasound-determined plaque mor-
hologic characteristics apart from stenosis as reliable pre-
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ventional, and medical management.
THE SVS POSITION FOR QUESTION 7.B.II IS THAT TCD
CAN DETECT MICROEMBOLIC EVENTS AND INCREASED FRE-
QUENCY OF THESE EVENTS IS ASSOCIATED WITH THE PRESENCE
OF UNSTABLE PLAQUES.
Although the data are not uniform,62 a recent review of
the available information indicated that TCD-detected mi-
croemboli are indeed correlated with degree of stenosis,
presence of silent cerebral infarcts, and increased risk of
neurologic symptom advent.61 This concept has not been
tested in clinical trials, and logistic considerations of avail-
ability and cost may constrain its widespread use.
THE SVS POSITION FOR QUESTION 7.B.III IS THAT MRI
SEEMS PROMISING IN THE ANALYSIS OF PLAQUE MORPHOLOGY
AND IN ANALYSIS OF TREATMENT RESULTS.
The ICSS study, in particular, focused attention on the
significant incidence of clinically silent, yet DW-MRI visu-
alized new brain lesions after carotid interventions in symp-
tomatic patients. Such lesions were found in some 50% of
CAS-treated patients vs 17% of CEA patients (OR, 5.1; P
.0001).40 The long-term sequela of such periprocedural
emboli are unknown, yet appropriately feared. Also, post-
procedure DW-MRI–detected brain infarcts can serve as
end points in future clinical trials.
A different issue relates to the use of high-resolution
MRI to characterize the at-risk plaque in asymptomatic
patients.60 In a recent prospective study of 154 asymptom-
atic patients presenting with 50% to 79% (ie, moderate)
stenosis and monitored for a mean of 38.2 months, Takaya
et al11 noted 12 cerebrovascular events. MRI findings at
study entry of thin or ruptured fibrous cap (OR, 17.2; P
.001), intraplaque hemorrhage (OR, 5.2; P .005), larger
area of intraplaque hemorrhage (OR for 10 mm2, 2.6; P
.006), larger lipid-rich or necrotic core (OR 10% increase,
1.6; P .004), and greater maximal wall thickness (OR for
1-mm increase, 1.6; P  .008) predicted clinical outcome.
Interestingly, in this study, incidence of TIA/stroke was 9%
at 38 months of follow-up, and 65% of the patients were
maintained on statin therapy. Thus, high-resolution MRI
imaging has the potential to characterize at-risk plaques;
however, cost considerations will likely constrain its wide-
spread application.
THE SVS POSITION FOR QUESTION 7.B.IV IS THAT IT IS
INCONCEIVABLE THAT ANY MODEL PREDICTING STROKE RISK IN
PATIENTS WITH ASYMPTOMATIC CAROTID DISEASE WOULD NOT
USE CAROTID STENOSIS SEVERITY AS ITS MAIN RISK INDICATOR.
We therefore believe that research efforts should be
focused on detection of plaque characteristics predictive of
stroke. Predictive models incorporating other patient clin-
ical characteristics should be combined with more reliable
noninvasive means for predicting plaque behavior.10 Per-
haps the best predictive model for symptomatic patients
was developed from the medical arm of the NASCET, and
this model incorporated degree of stenosis as well as the
presence of plaque ulceration. Furthermore in this study,
the degree of stenosis alone was a strong predictor of
outcome for medically managed patients.56 Although the segree of stenosis is presently the best available surrogate
or risk prediction in asymptomatic patients, as seen in the
nswers to questions 7.b.i and 7.b.iii, it appears that other
easurable plaque characteristics will be major determi-
ants of prognosis as well as response to treatment.
MEDCAC panel voting results. This was a nonvot-
ng question.
OMMENTARY
As detailed herein, the SVS position statements to the
MS MEDCAC have largely been derived from our re-
ently updated carotid disease practice guidelines,1 and the
osition statements on the research questions are entirely
onsistent with same. Similar to the posture of the MED-
AC panel, the SVS practice guidelines reflect best avail-
ble evidence rather than personal experience, or for exam-
le, claims about the adequacy of medical therapy that are
erived from literature projections rather than from high-
uality clinical trials. It was repeatedly emphasized to the
EDCAC panel members, and to the presenters, that the
onsideration was to the available evidence rather than
linician experience.
The MEDCAC panel votes were concordant with the
VS position statements and practice guidelines in the
mportant questions related to the natural history and
troke risk of asymptomatic (severe) carotid stenoses and in
he prediction of adverse events after CEA. Both of these
onsiderations are fundamental to clinical decision making.
erhaps the most striking concordance between the SVS
osition and the MEDCAC panel vote related to the treat-
ent of symptomatic carotid stenoses, where the panel had
ore than an intermediate level of confidence that CEA is
he favorite treatment strategy for such patients. The panel
cores for CAS and BMT in these patients were both in the
ow-confidence realm. No doubt, most clinicians (possibly
xcepting vociferous advocates of CAS) would respond
ith “of course.” It is important, once again, to emphasize
hat the best available trial data (CREST) and the most
ecent meta-analysis of all available trial data continue to
emonstrate a twofold increase in the risk of stroke/death
hen CAS is used rather than CEA to treat symptomatic
atients.23-25 Despite the criticism referable to CAS oper-
tor expertise leveled at the European trials, CREST has
hown that even in the hands of the highly selected and
dmittedly expert interventionalists, CAS has a twofold
ncreased stroke risk compared with CEA in the treatment
f symptomatic carotid stenoses.
In the realm of asymptomatic patients, the research
uestions were influenced (in terms of panel voting) by
arsing them in consideration of procedural risk (ie, for
EA) and qualifying patients by whether they were at high
isk for stroke. There was low confidence, in the panel’s
iew, that intervention of any kind vs BMT was the favored
pproach to asymptomatic stenoses. If asymptomatic ca-
otid atherosclerosis were characterized as not being at high
isk for stroke, then there was a high level of confidence that
MT is the appropriate treatment. This is, of course, con-
istent with the SVS position, although clinicians at the
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stenosis as the single best surrogate for stroke risk in pa-
tients with asymptomatic lesions. As reviewed herein, al-
though this is an imperfect surrogate, it is in fact reliable
and useful, based on the best available natural history
data.10,56
That fact notwithstanding, the SVS has identified in-
vestigation in the realm of asymptomatic carotid stenoses as
its number one clinical research priority. The further char-
acterization of asymptomatic plaques with a variety of
imaging modalities is likely to add valuable information to
the degree of stenosis in clinical decision making. The SVS
supports the position that future trials in asymptomatic
patients should include an optimal medical therapy arm.
However, as reviewed herein, the contention that modern
medical therapy has obviated the need for intervention in
asymptomatic patients is unsubstantiated.
The further course, utilization, and outcomes of the
CMS MEDCAC are not clearly defined at the moment.
Obviously, it will be a repository of information should
CMS choose to reopen the issue of the NCD for CAS.
Contributing to this article or the MEDCAC, or both,
were Richard P. Cambria, MD, SVS President; Peter
Glovickzi, MD, SVS President-Elect; Julie Frieschlaig,
MD, SVS Vice-President; John Ricotta, MD, SVS Secre-
tary; R. Clement Darling, III, MD, SVS Treasurer; Kim-
berly Hansen, MD, Chair SVS Fellows Council; Robert
Zwolak, MD, SVS immediate Past-President; Daniel Clair,
MD, Chairman, Department of Vascular Surgery, Cleve-
land Clinic Foundation; William Mackey, MD, Chairman,
Department of Surgery, Tufts Medical Center, Boston; and
Ali AbuRhama, MD, Chief Vascular Surgery, University of
West Virginia.
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